This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Dozen Years of Experience

Barry J. Materson, MD; Richard A. Preston, MD

Arch Intern Med. 1994;154(5):513-523.

Abstract
Introduction of the first angiotensin-converting enzyme (ACE) inhibitor, captopril, in 1981 marked a major advance in the treatment of essential hypertension. This article reviews the 12 years of clinical experience during which it and other ACE inhibitors have become recognized as first-line agents for treating hypertension. The benefits of ACE inhibition in diabetic patients are being defined. In recent years, beneficial effects on glucose handling, leftventricular mass, quality of life, renal function, and myocardial protection have become recognized. For these reasons, and because of their excellent safety profile, ACE inhibitors are now widely used for the treatment of hypertensive patients. (Arch Intern Med. 1994;154:513-523)

Author Affiliations
From the Medical and Research Services, Department of Veterans Affairs Medical Center, Miami, Fla, and Department of Medicine, University of Miami.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats
Jiang et al.
J. Appl. Physiol. 2007;102:2098-2103.
ABSTRACT | FULL TEXT  

Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in Mice.
Wysocki et al.
Clin. Cancer Res. 2006;12:4095-4102.
ABSTRACT | FULL TEXT  

Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension
Hannedouche et al.
Journal of Renin-Angiotensin-Aldosterone System 2001;2:246-254.
ABSTRACT  

Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise
Gavin et al.
J. Appl. Physiol. 2000;88:1690-1697.
ABSTRACT | FULL TEXT  

Guinea Pig Airway Hyperresponsiveness Induced by Blockade of the Angiotensin II Type 1 Receptor . Role for Endogenous Nitric Oxide
KANAZAWA et al.
Am. J. Respir. Crit. Care Med. 1999;159:165-168.
ABSTRACT | FULL TEXT  

Education-Specific Estimates of Life Expectancy and Age-Specific Disability in the U.S. Elderly Population 1982 to 1991
Manton et al.
J Aging Health 1997;9:419-450.
ABSTRACT  

Chronic disability trends in elderly United States populations: 1982-1994
Manton et al.
Proc. Natl. Acad. Sci. USA 1997;94:2593-2598.
ABSTRACT | FULL TEXT  

Functional and Biochemical Analysis of Angiotensin II–Forming Pathways in the Human Heart
Wolny et al.
Circ. Res. 1997;80:219-227.
ABSTRACT | FULL TEXT  

Angiotensin II Receptor Inhibition: A New Therapeutic Principle
Messerli et al.
Arch Intern Med 1996;156:1957-1965.
ABSTRACT  

The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs
Bauer and Reams
Arch Intern Med 1995;155:1361-1368.
ABSTRACT